Tagged with GE

Egypt As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here, three regional managers give their takes on what Egypt means to their companies, and their hopes for its future development.…

China A roundup of some of the biggest healthcare and pharma news from China including the exclusion of Pfizer’s Paxlovid from the country’s national insurance coverage, CanSino’s promising mRNA booster trial results, WuXi Biologics and GSK’s T-cell engager deal, Biocytogen and Hansoh’s antibody collaboration …   Pfizer CEO rules out generic…

Germany Home to Europe’s largest pharma market, a host of industry giants, a thriving biotech scene, and a public healthcare system undergoing significant reform, Germany is indisputably one of the world’s most important life science nations.   An overview of the pharma industry in Germany. Made with Visme Infographic Maker   The…

Africa Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the European Medicines Agency, and its progress thus far. Hwenda also examines how the AMA stands to impact Africa’s clinical trial…

Germany In response to a looming deficit of EUR 17 billion, Germany’s new Financial Stabilization of Statutory Health Insurance System Act (GKV-Finanzstabilisierungsgesetz, or GKV-FinStG) is aimed at containing costs in the country’s health insurance system by distributing the financial burden amongst all healthcare stakeholders, yet biopharma companies stand to be hit…

Americas Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth and plans to launch 14 new products there by 2025, most importantly its European Medicines Agency-approved dengue vaccine. She also…

Global Over the past year, PharmaBoardroom has spoken to pharma executives the world over, collecting unique perspectives from all sides of the industry. Here are the ten most-read interviews of 2022 that range from conversations with one of Korea’s top CDMOs to the American generics association and the Italian regulatory agency,…

Europe Based on current discussions by the European Commission, launch conditionalities would not account for the distinct nature of small and mid-sized companies, OMPs and ATMPs. EUCOPE’s Alexander Natz breaks down this aspect of the revision of the general pharmaceutical legislation and why it would prove unsustainable for smaller companies and…

Egypt While evidence and recognition are growing that gender-balanced and diverse management teams at all levels of hierarchies produce positive business outcomes, the MENA region still has a long road to travel in this respect. Only 11 percent of senior management positions in MENA firms and just four percent of board…

Global PharmaBoardroom’s network of thought leaders continued to provide some of our top content in 2022, covering topics such as Africa’s first integrated drug discovery platform,  Chinese vaccine exports, inequities in US healthcare, antimicrobial pollution and new pharmaceutical legislation in Europe. See our dedicated op-ed page for all of the year’s contributions…

Alvion John Bouros of Greek generics start-up Alvion outlines the company’s rapid development since its foundation back in 2014, its product and market selection strategy within Europe, partnerships, business development, and his ambitious goals for the firm’s future.   [We have] confidence that we will soon become one of the leading…

Americas In 2019 the pharma industry financed some 700 clinical studies in Latin America with investments of more than USD one billion and according to FIFARMA, the leading association of innovators in the region, LatAm currently supports about 10 percent of the world’s clinical research. Local industry leaders discuss the advantages…